Navigation Links
Experimental drug shows promise for treatment-resistant leukemias
Date:4/8/2014

Research in mice and human cell lines has identified an experimental compound dubbed TTT-3002 as potentially one of the most potent drugs available to block genetic mutations in cancer cells blamed for some forms of treatment-resistant leukemia.

Results of the research by Johns Hopkins Kimmel Cancer Center investigators, described March 6 in the journal Blood, show that two doses a day of TTT-3002 eliminated leukemia cells in a group of mice within 10 days. The treatment performed as well as or better than similar drugs in head-to-head comparisons.

More than 35 percent of acute myeloid leukemia (AML) patients harbor a mutation in the gene FMS-like tyrosine kinase-3 (FLT3). Normal FLT3 genes produce an enzyme that signals bone marrow stem cells to divide and replenish. But when FLT3 is mutated in some AML patients, the enzyme stays on permanently, causing rapid growth of leukemia cells and making the condition likely to relapse after treatment.

Many investigators are developing and testing drugs designed to block the FLT3 enzyme's proliferation, several of which are now in clinical trials. So far, their effectiveness has been limited, according to Donald Small, M.D., Ph.D., the Kyle Haydock Professor of Oncology and director of pediatric oncology at Johns Hopkins. Small led a team of researchers who originally cloned the FLT3 gene and linked it to leukemia a decade ago.

"We're very excited about TTT-3002, because it appears in our tests so far to be the most potent FLT3 inhibitor to date," says Small. "It showed activity against FLT3-mutated cells taken from patients and with minimal toxicity to normal bone marrow cells, making it a promising new candidate for the treatment of AML."

In a series of experiments with the drug, Small, postdoctoral fellow Hayley Ma, Ph.D., and others found that the amount of TTT-3002 needed to block FLT3 activity in human leukemia cell lines was six- to sevenfold lower tha
'/>"/>

Contact: Vanessa Wasta
wasta@jhmi.edu
410-614-2916
Johns Hopkins Medicine
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Diabetes drug shows promise in reducing Alzheimers disease in an experimental model
2. Experimental drug could enhance multiple myeloma and myeloid leukemia therapies
3. Experimental drug shows encouraging results in treating most common form of lung cancer
4. Studies of experimental hepatitis C drug show promise for preventing recurrence in liver transplant
5. ASSURE study of experimental agent to raise HDL yields disappointing and surprising results
6. York physicists offer novel insight into experimental cancer treatment
7. Experimental Drug Shows Benefits Against Melanoma in Early Study
8. Experimental Drugs Show Promise Against Prostate Cancer
9. Experimental Drug Seems to Aid Memory in Mice With Alzheimers
10. Mayo Clinic finds experimental drug inhibits growth in all stages of common kidney cancer
11. Experimental Drug for Hepatitis C Promising, Studies Show
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... of a cancer diagnosis may improve health outcomes for ... by a researcher at the University of Houston (UH). ... intervention is the writing instruction. Otherwise, writing is just ... journal can be therapeutic, but oftentimes we don,t get ... not," said Qian Lu, assistant professor and director of ...
(Date:8/1/2014)... August 01, 2014 Hot off the presses ... spa category of the World’s Best Awards by Travel ... month-long celebration of National Relaxation Day (technically August 15). ... of MAJOR experts to help guests celebrate relaxation throughout the ... is for health and wellness to carve out time to ...
(Date:8/1/2014)... Alan Mozes HealthDay Reporter ... the country, barbershops serve as a time-honored destination for a ... see whether barbershops might also be the spot to tackle ... men. In a novel partnership, the U.S. Centers for ... of Health (MSDH), enlisted the help of barbershop staff to ...
(Date:8/1/2014)... Abington, PA (PRWEB) August 01, 2014 ... beneficial than bottle-feeding. A recent study conducted ... may not lag too far behind in terms of ... simply want to know what’s best for their baby. ... , According to Dr. Steven Shapiro , chair ...
(Date:8/1/2014)... GlobalDatas new report, "United ... provides key market data on the United ... value, in millions of US dollars, volume ... dollars) within market segments - Electrosurgical RF ... Plasma Coagulation Generators. , To view the ...
Breaking Medicine News(10 mins):Health News:Expressive writing may help breast cancer survivors 2Health News:Expressive writing may help breast cancer survivors 3Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 2Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 3Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 4Health News:Barbershops Join Fight Against High Blood Pressure in Black Men 2Health News:Barbershops Join Fight Against High Blood Pressure in Black Men 3Health News:Despite Recent Study, Abington Health Expert Encourages Breastfeeding 2Health News:Despite Recent Study, Abington Health Expert Encourages Breastfeeding 3Health News:United Kingdom Surgical Generators Market Size, Share, Analysis, Trends and Forecasts 2020 2Health News:United Kingdom Surgical Generators Market Size, Share, Analysis, Trends and Forecasts 2020 3
... DIEGO, Feb. 27 Can you really trust the search results ... although it was published in 2005, the San Diego Union ... Yahoo search results as if it were hot of the presses. ... finally tell their side of the story. "We were quiet ...
... cabergoline cut consumption, were less prone to relapse , , ... prescribed to help with infertility and menstrual disorders may ... When injected with cabergoline (Dostinex), rats addicted to alcohol ... less prone to relapsing, a study by researchers at ...
... Brookdale Senior Living Inc. (NYSE: BKD ) announced ... a Second Amended and Restated Credit Agreement. The amended ... and matures in August 2010. Additionally, the Company announced ... credit facilities of up to $48.5 million in the aggregate. ...
... 27 LCA-Vision Inc. (Nasdaq: LCAV ) ... independent research and proxy advisory firm, today recommended that ... of Directors and reject all of the proposals, including ... replacement Directors, in the Joffe Group,s consent solicitation. ...
... Health ReformCHICAGO, Feb. 27 The American College ... Medicare,s broken physician payment system included in President ... yesterday. In addition, the College applauds the ... effort to expand access, improve quality, and reduce ...
... patient-physician relationship is entitled to "exceptional ... In a legal victory that preserves ... an Arkansas state court has ruled ... system, acted improperly by inappropriately restricting ...
Cached Medicine News:Health News:Valenti International Responds to the San Diego Union Tribune Article 'Can't buy me love,' Fraught With Inaccuracies and Slanted for Sensationalism, Journalistic Integrity Appears Lost. 2Health News:Valenti International Responds to the San Diego Union Tribune Article 'Can't buy me love,' Fraught With Inaccuracies and Slanted for Sensationalism, Journalistic Integrity Appears Lost. 3Health News:Valenti International Responds to the San Diego Union Tribune Article 'Can't buy me love,' Fraught With Inaccuracies and Slanted for Sensationalism, Journalistic Integrity Appears Lost. 4Health News:Hormone Drug May Help Drinkers Stay Sober 2Health News:Brookdale Amends and Extends Corporate Line of Credit 2Health News:Brookdale Amends and Extends Corporate Line of Credit 3Health News:Glass Lewis Recommends Shareholders Support LCA-Vision Board of Directors and Reject All Three Proposals by Dissident Joffe Group 2Health News:Glass Lewis Recommends Shareholders Support LCA-Vision Board of Directors and Reject All Three Proposals by Dissident Joffe Group 3Health News:Glass Lewis Recommends Shareholders Support LCA-Vision Board of Directors and Reject All Three Proposals by Dissident Joffe Group 4Health News:American College of Surgeons Supports Steps to Shore Up Medicare Payment System In Proposed Federal Budget 2Health News:Physicians Hail Arkansas Court Victory Against Baptist Health 2
(Date:8/1/2014)... 2014  VanDeMark Chemical Inc., Lockport, ... phosgene and phosgene derivatives in North ... acquired Framochem Kft, a leading European-based manufacturer of ... . The purchase unites two companies ... the world,s largest, independent manufacturers of products based ...
(Date:8/1/2014)... LAKE FOREST, Ill. , Aug. 1, 2014 ... private equity firm focused exclusively on the healthcare ... Inc. ("Vesta") to The Lubrizol Corporation ("Lubrizol"). Lubrizol, ... company that produces and supplies technologies to customers ... Terms of the transaction were not disclosed. ...
(Date:8/1/2014)... Research and Markets has ... Biosensors Market 2014-2018" report to their offering. ... Medical biosensors are used to analyze biological ... biosensors monitor health status, disease betterment, and therapeutic ... are cost-effective and user-friendly devices. Also, they are ...
Breaking Medicine Technology:VanDeMark Chemical Inc. Acquires Framochem 2VanDeMark Chemical Inc. Acquires Framochem 3VanDeMark Chemical Inc. Acquires Framochem 4RoundTable Healthcare Partners Announces Sale of Vesta Funding, Inc. to The Lubrizol Corporation 2Global Medical Biosensors Market 2014-2018: Key Vendors are Abbott, Bayer, LifeScan and F. Hoffmann-La Roche 2
... the DiamondTome™ Skin Resurfacing System for ... Wands, an evolution in microdermabrasion technology ... more youthful skin. , For skin ... of DiamondTome's™ innovative approach to skin ...
... hair reduction and skin rejuvenation Intense ... use within a clinic or medspa ... in a single portable device. Used ... hair, photo rejuvenation and active acne, ...
... Start or expand your aesthetic practice with ... the cost-effective system that's gentle, powerful and ... the exciting benefits of IPL Skin Treatments ... promises to be an indispensable tool for ...
Standard Lipo-tubing...
Medicine Products: